Teriparatide

特立帕肽

Report date: 2024/05/14 13:05:07

Base Information

Drug NameTeriparatide
Drug Alias NameTeriparatide injection特利帕肽EB613 (口服人甲状旁腺激素(1-34))TeriparatidumParathyroid hormone (1-34) +[12] 
ClassificationBiologics > Protein drugs > Recombinant polypeptideBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionParathyroid hormone replacements
TargetsParathyroid hormone receptor
Therapy Area/IndicationsMenopausal symptomsAnorexia NervosaFemoral Neck Fractures +[20] 
Global Approved IndicationsOsteoporosis, PostmenopausalOsteoporosis
Approved Indications in ChinaOsteoporosis, PostmenopausalOsteoporosis
Original Approved Country/TerritoryUnited States
Original Approved Date2002/11/26
Country/TerritoryCzechiaBelgiumCanada +[40] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesSaint Petersburg State University, RussiaEli Lilly And CompanyUniversity Of Calgary +[5] 
Inactive CompaniesUniversity Of California San FranciscoTranspharma MedicalNational Institute Of Arthritis And Musculoskeletal And Skin Diseases +[10] 
Active IndicationsAnkle FracturesFractures, BoneHypoparathyroidism +[10] 
Inactive IndicationsMenopausal symptomsAnorexia NervosaFemoral Neck Fractures +[10] 

Other Information

ATC CodeH05AA02
Related LinksWikipediaDrugBankKEGG